TY  - JOUR
AU  - Hegenbart, Ute
AU  - Bochtler, Tilmann
AU  - Benner, Axel
AU  - Becker, Natalia
AU  - Kimmich, Christoph
AU  - Kristen, Arnt V
AU  - Beimler, Jörg
AU  - Hund, Ernst
AU  - Zorn, Markus
AU  - Freiberger, Anja
AU  - Gawlik, Marianne
AU  - Goldschmidt, Hartmut
AU  - Hose, Dirk
AU  - Jauch, Anna
AU  - Ho, Anthony D
AU  - Schönland, Stefan O
TI  - Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
JO  - Haematologica
VL  - 102
IS  - 8
SN  - 1592-8721
CY  - Pavia
PB  - Ferrata Storti Foundation
M1  - DKFZ-2017-04074
SP  - 1424 - 1431
PY  - 2017
AB  - Chemotherapy in light chain amyloidosis aims to normalize the involved free light chain in serum, which leads to an improvement, or at least stabilization of organ function in most responding patients. We performed a prospective single center phase 2 trial with 50 untreated patients not eligible for high-dose treatment. The treatment schedule comprised 6 cycles of oral lenalidomide, melphalan and dexamethasone every 4 weeks. After 6 months, complete remission was achieved in 9 patients (18
LB  - PUB:(DE-HGF)16
C6  - pmid:28522573
C2  - pmc:PMC5541875
DO  - DOI:10.3324/haematol.2016.163246
UR  - https://inrepo02.dkfz.de/record/128052
ER  -